Harrow (HROW) Projected to Post Earnings on Thursday

Harrow (NASDAQ:HROW) will likely be releasing its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect the company to announce earnings of $0.40 per share for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, March 3, 2026 at 8:00 AM ET.

Harrow Stock Up 2.2%

Shares of NASDAQ HROW opened at $34.00 on Tuesday. The stock has a market capitalization of $1.27 billion, a P/E ratio of -199.99 and a beta of 0.05. The company has a 50-day moving average price of $44.26 and a 200-day moving average price of $43.52. Harrow has a 1 year low of $20.85 and a 1 year high of $54.85. The company has a debt-to-equity ratio of 4.67, a current ratio of 2.20 and a quick ratio of 2.06.

Institutional Trading of Harrow

Several hedge funds have recently added to or reduced their stakes in HROW. University of Texas Texas AM Investment Management Co. bought a new position in shares of Harrow during the 4th quarter worth $26,000. Raymond James Financial Inc. purchased a new stake in Harrow during the second quarter valued at about $48,000. Tower Research Capital LLC TRC lifted its holdings in Harrow by 345.0% during the second quarter. Tower Research Capital LLC TRC now owns 3,373 shares of the company’s stock valued at $103,000 after purchasing an additional 2,615 shares during the last quarter. Larson Financial Group LLC boosted its position in Harrow by 848.2% during the third quarter. Larson Financial Group LLC now owns 2,162 shares of the company’s stock worth $104,000 after purchasing an additional 1,934 shares during the period. Finally, Strs Ohio bought a new position in Harrow during the first quarter worth about $149,000. Institutional investors own 72.76% of the company’s stock.

Analyst Ratings Changes

HROW has been the topic of several recent research reports. BTIG Research reaffirmed a “buy” rating and issued a $63.00 price target on shares of Harrow in a research report on Wednesday, March 18th. Cantor Fitzgerald decreased their price objective on Harrow from $94.00 to $91.00 and set an “overweight” rating for the company in a report on Wednesday, March 4th. William Blair reissued an “outperform” rating on shares of Harrow in a research note on Tuesday, March 3rd. Zacks Research downgraded Harrow from a “hold” rating to a “strong sell” rating in a research note on Tuesday, March 3rd. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Harrow in a report on Thursday, January 22nd. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $71.14.

Harrow Company Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.